In Section C, members will acquire ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Individuals will acquire treatment until eventually disease progression or the contributors are unable to tolerate the study drugs. There may be larger treatment stress for participants Within this trial when compared https://abbv-744forsmallcelllungc25689.blogs100.com/32492882/how-much-you-need-to-expect-you-ll-pay-for-a-good-abbv-744-combination-therapy-with-chemotherapy